Researchers have uncovered a key cellular communication network that drives resistance to gemcitabine in pancreatic cancer. By integrating bulk, single-cell and spatial transcriptomics with experimental validation, the study identifies crosstalk between PRRX2-positive epithelial cells and SPP1-positive macrophages as a central mechanism promoting tumor aggressiveness and poor prognosis. The findings highlight new biomarkers and suggest potential combination treatment strategies to overcome chemotherapy resistance.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Prostate Cancer Foundation (PCF) are pleased to announce that Anil Parsram Bidkar, PhD, assistant professional researcher in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF), has been selected as the recipient of a $225,000 Young Investigators Award. The grant, which is cosponsored by the SNMMI Mars Shot Fund and PCF, was awarded based on his proposal, "CD46-targeted dual-isotope and hybrid pre-targeted radiotherapy platform to overcome tumor heterogeneity in prostate cancer."

ROS serve as crucial mediators of redox homeostasis, playing decisive roles in diverse pathological processes. While inorganic sonosensitizers for SDT represent significant advances in ROS-based therapeutics, developing US-responsive sonosensitizers with optimal biocompatibility, and initiating innovative treatment strategies remains a substantial translational challenge. In this work, researchers demonstrate that FeOOH nanorods function as exceptional tribocatalysts capable of efficiently converting vibrational mechanical energy into therapeutic effects through sono-tribocatalytic activation.

New research from Memorial Sloan Kettering Cancer Center (MSK) discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.

Fear that their cancer will progress or worsen is one of the most common concerns among people living with this disease. Several studies indicate that between 20% and 70% of cancer patients experience significant levels of anxiety related to the progression of their health. Identifying and measuring this concern is key to providing appropriate psychological care and improving patients’ quality of life. This has been the aim of a study led by the University of Barcelona (UB), the Universitat Rovira i Virgili (URV) and CEU-San Pablo University, which for the first time has validated in the Spanish population the Spanish version of the Assessment of Survivor Concerns (ASC) questionnaire, a brief tool specifically designed to assess cancer- and health-related concerns.

A randomized crossover pilot study conducted by researchers at the University of Sherbrooke and the Research Centre on Aging in Quebec, Canada, investigated whether moderate-to-high-intensity aerobic exercise performed the day before chemotherapy could influence cancer-related fatigue and active versus sedentary behaviors in the days following treatment. The study, published in Translational Exercise Biomedicine (ISSN: 2942-6812), an official partner journal of International Federation of Sports Medicine (FIMS), provides preliminary evidence that pre-chemotherapy exercise is safe and may offer modest benefits for fatigue management.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce that Chun Li, PhD, professor of chemistry in the Department of Cancer Systems Imaging at MD Anderson Cancer Center in Houston, has been selected as the recipient of a $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award from the 2026 Mars Shot Fund. The Alavi Mars Shot Award is focused on advancing imaging research in infection and inflammation, and Li's grant was awarded based on his proposal, "Imaging vascular inflammation and response to therapy in atherosclerotic coronary artery disease."